OMERS ADMINISTRATION Corp Has $1.62 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

OMERS ADMINISTRATION Corp lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 21.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,192 shares of the company's stock after buying an additional 1,279 shares during the period. OMERS ADMINISTRATION Corp's holdings in Cencora were worth $1,616,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of COR. Miracle Mile Advisors LLC purchased a new stake in Cencora in the 4th quarter worth approximately $273,000. Signal Advisors Wealth LLC grew its stake in Cencora by 19.5% in the fourth quarter. Signal Advisors Wealth LLC now owns 1,831 shares of the company's stock valued at $411,000 after purchasing an additional 299 shares in the last quarter. Oak Thistle LLC acquired a new position in Cencora in the 4th quarter worth about $455,000. Fifth Third Wealth Advisors LLC raised its stake in shares of Cencora by 11.8% during the 4th quarter. Fifth Third Wealth Advisors LLC now owns 1,958 shares of the company's stock worth $440,000 after purchasing an additional 206 shares in the last quarter. Finally, Kathmere Capital Management LLC lifted its holdings in shares of Cencora by 14.6% during the 4th quarter. Kathmere Capital Management LLC now owns 2,091 shares of the company's stock valued at $470,000 after buying an additional 266 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on COR. Citigroup increased their price objective on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Robert W. Baird raised their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Bank of America raised their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $301.18.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of COR traded up $2.15 during trading hours on Monday, reaching $292.37. 1,553,490 shares of the company traded hands, compared to its average volume of 1,544,787. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock's fifty day moving average is $279.87 and its 200 day moving average is $255.76. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35. The stock has a market cap of $56.70 billion, a P/E ratio of 41.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $3.80 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio is 25.52%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.